HYDROCHLOROTHIAZIDE TABLETS USP, 2083, 2089, Rx only

/HYDROCHLOROTHIAZIDE TABLETS USP, 2083, 2089, Rx only
HYDROCHLOROTHIAZIDE TABLETS USP, 2083, 2089, Rx only2018-09-06T09:12:40+00:00

Prescription Drug Name:

HYDROCHLOROTHIAZIDE TABLETS USP, 2083, 2089, Rx only

ID:

c9c44c37-bb49-4364-9293-3c8fd51b759e

Code:

34391-3

DESCRIPTION


id: 35596a65-503c-409b-9fea-06c5026f5b8d
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Hydrochlorothiazide USP is a diuretic and antihypertensive. It is the 3,4-dihydro derivative of chlorothiazide. It is chemically designated as 6-chloro-3,4-dihydro-2 H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide and has the following structural formula: C7H8ClN3O4S2 M.W. 297.74 Hydrochlorothiazide, USP is a white, or practically white, crystalline powder which is slightly soluble in water, freely soluble in sodium hydroxide solution, in n-butylamine, and in dimethylformamide; sparingly soluble in methanol; insoluble in ether, in chloroform, and in dilute mineral acids. Each tablet for oral administration contains 25 mg or 50 mg hydrochlorothiazide USP. In addition, each tablet contains the following inactive ingredients: corn starch, dibasic calcium phosphate, FD&C Yellow No. 6 Lake, lactose monohydrate and magnesium stearate.

CLINICAL PHARMACOLOGY


id: 61df9a2d-f6bc-4685-a147-d6ffbd97bc4f
displayName: CLINICAL PHARMACOLOGY SECTION
FDA Article Code: 34090-1

The mechanism of the antihypertensive effect of thiazides is unknown. Hydrochlorothiazide does not usually affect normal blood pressure. Hydrochlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are approximately equal in their diuretic efficacy. Hydrochlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. After oral use diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.

INDICATIONS AND USAGE


id: 5383470a-2bc6-4172-814e-c3ecda20c17c
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

CONTRAINDICATIONS


id: d0a2de4f-b1ca-4995-9bcc-188967004a96
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

Anuria. Hypersensitivity to this product or to other sulfonamide-derived drugs.

WARNINGS


id: 62ec3b1b-4d63-4db5-9ffb-85774c041096
displayName: WARNINGS SECTION
FDA Article Code: 34071-1

Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Thiazides may add to or potentiate the action of other antihypertensive drugs. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic lupus erythematosus has been reported. Lithium generally should not be given with diuretics (see PRECAUTIONS, Drug Interactions).

ADVERSE REACTIONS


id: 3d13fd48-2752-45e1-ba31-560484ade5db
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity.

OVERDOSAGE


id: 85729162-7e05-43b4-9a31-f39bcbbd7775
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. In the event of overdosage, symptomatic and supportive measures should be employed. Emesis should be induced or gastric lavage performed. Correct dehydration, electrolyte imbalance, hepatic coma and hypotension by established procedures. If required, give oxygen or artificial respiration for respiratory impairment. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in the mouse and rat.

DOSAGE AND ADMINISTRATION


id: 5596acff-5119-4d3b-b6ba-255b212da5ce
displayName: DOSAGE & ADMINISTRATION SECTION
FDA Article Code: 34068-7

Therapy should be individualized according to patient response. Use the smallest dosage necessary to achieve the required response.

HOW SUPPLIED


id: e210d4b9-5ddb-4f42-81ff-367c1d6f9d8c
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

Hydrochlorothiazide Tablets USP, 25 mg are available as round, light orange, flat face, beveled edge tablets, bisected on one side, debossed “2083” and “TEVA” on the other side, containing 25 mg hydrochlorothiazide USP, packaged in bottles of 30 (NDC 42708-028-30) tablets. Dispense in a well-closed container as defined in the USP, with a child-resistant closure (as required). Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Manufactured In Czech Republic By: TEVA CZECH INDUSTRIES s.r.o. Opava-Komarov, Czech Republic Manufactured For: TEVA PHARMACEUTICALS USA, INC. North Wales, PA 19454 Rev. H 5/2016

Package/Label Display Panel


id: 1ea9563b-eb11-444b-8b09-82fcb664a5a1
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4